15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $65343 | -$85M | 0.0% | -132871.3% | -$89M | — | $44M |
| 2024 | $217756 | -$107M | 0.0% | -51616.9% | -$105M | — | $66M |
| 2023 | $832010 | -$135M | 0.0% | -17300.3% | -$125M | — | $14M |
| 2022 | $10M | -$280M | 0.0% | -2607.4% | -$217M | — | $46M |
| 2021 | $2M | -$304M | 0.0% | -16972.3% | -$217M | — | $71M |
| 2020 | $7M | -$166M | 0.0% | -1674.2% | -$179M | — | $251M |
| 2019 | $4M | -$119M | 0.0% | -2702.1% | -$99M | — | $22M |
| 2018 | $30M | -$97M | 0.0% | -308.7% | -$76M | $0 | $24M |
| 2017 | $42M | -$88M | 0.0% | -198.1% | -$74M | — | $24M |
| 2016 | $35M | -$74M | 0.0% | -215.5% | -$65M | — | $19M |
| 2015 | — | -$29M | — | — | -$15M | — | $58M |
| 2014 | — | -$36M | — | — | -$31M | — | $41M |
| 2013 | — | -$66M | — | — | -$16M | — | $34M |
| 2012 | — | -$20M | — | — | -$23M | — | $6M |
| 2011 | — | -$15M | — | — | -$20M | — | $17M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$20M | — | — | -$22M | — | $26M |
| Dec '25 | $0 | $4M | — | — | -$19M | — | $44M |
| Sep '25 | $0 | -$45M | — | — | -$22M | — | $37M |
| Jun '25 | $0 | -$24M | — | — | -$21M | — | $24M |
| Mar '25 | $65343 | -$20M | 0.0% | -38337.0% | -$27M | — | $40M |
| Dec '24 | $116994 | -$19M | 0.0% | -17410.8% | -$20M | — | $66M |
| Sep '24 | $0 | -$25M | — | — | -$27M | — | $22M |
| Jun '24 | $100762 | -$32M | 0.0% | -32945.9% | -$29M | — | $34M |
| Mar '24 | $0 | -$30M | — | — | -$29M | — | $20M |
| Dec '23 | $102651 | -$25M | 0.0% | -26686.3% | -$26M | — | $14M |
| Sep '23 | $388446 | -$34M | 0.0% | -9152.6% | -$29M | — | $19M |
| Jun '23 | $225971 | -$36M | 0.0% | -16392.0% | -$32M | — | $53M |
| Mar '23 | $114943 | -$41M | 0.0% | -38238.2% | -$37M | — | $28M |
| Dec '22 | $124666 | -$54M | 0.0% | -44876.8% | -$37M | — | $46M |
| Sep '22 | $9M | -$38M | 0.0% | -390.6% | -$68M | — | $22M |
| Jun '22 | $784395 | -$108M | 0.0% | -13276.1% | -$51M | — | $41M |
| Mar '22 | $199074 | -$79M | 0.0% | -36033.3% | -$62M | — | $59M |
| Dec '21 | $839115 | -$107M | 0.0% | -12573.8% | -$39M | — | $71M |
| Sep '21 | $291698 | -$60M | 0.0% | -20553.2% | -$47M | — | $68M |
| Jun '21 | $272824 | -$82M | 0.0% | -30496.6% | -$79M | — | $59M |
How the market has priced INO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, INOVIO PHARMACEUTICALS, INC.'s revenue has declined 61.2% per year. These are computed facts, not advice.
As of FY2025, INOVIO PHARMACEUTICALS, INC. reported — of total debt against $44M of cash.
In FY2025, gross margin was —, operating margin -132871.3%, and net margin -130082.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.